Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

NCT03834948 is registered in ClinicalTrials.gov with Arch Oncology as lead sponsor.

NCT NCT03834948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03834948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176
Lead sponsor
Arch Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
February 4, 2019
Completion date
February 15, 2023
Enrollment
57 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor